Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
…, C Verslype, CJ Zech, D Arnold, E Martinelli - Annals of …, 2018 - annalsofoncology.org
The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last 20
years and is expected to increase until 2030 in some countries including the United States, …
years and is expected to increase until 2030 in some countries including the United States, …
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
E Martinelli, R De Palma, M Orditura… - Clinical & …, 2009 - academic.oup.com
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor
involved in the proliferation and survival of cancer cells. EGFR is the first molecular target …
involved in the proliferation and survival of cancer cells. EGFR is the first molecular target …
Solid-state gas sensors for breath analysis: A review
… F E NO is also allegedely … , F E NO detectors are currently available and their extensive
use provided more evidences to the supposed relationship between the concentration of F E NO …
use provided more evidences to the supposed relationship between the concentration of F E NO …
p63 identifies keratinocyte stem cells
…, E Dellambra, O Golisano, E Martinelli… - Proceedings of the …, 2001 - National Acad Sciences
… A, B, D, and E), it was possible to observe cells expressing PCNA but not p63 (see red
asterisks in B and E). These latter cells often flanked p63 + cells (B and E). Most frequently, cells …
asterisks in B and E). These latter cells often flanked p63 + cells (B and E). Most frequently, cells …
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
…, P Osterlund, T Yoshino, E Martinelli - Annals of …, 2023 - annalsofoncology.org
Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
…, V Zagonel, F Leone, I Depetris, E Martinelli… - The Lancet …, 2016 - thelancet.com
Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
[HTML][HTML] Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Colorectal cancer (CRC) is the third most common tumour in men and the second in women,
accounting for 10% of all tumour types worldwide. Incidence is 25% higher in males and …
accounting for 10% of all tumour types worldwide. Incidence is 25% higher in males and …
Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors
… In this study, the application of an electronic nose to the analysis of breath from patients … In
this work, an electronic nose based on eight of such compounds was used. The sensors were …
this work, an electronic nose based on eight of such compounds was used. The sensors were …
HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells
J Arthos, C Cicala, E Martinelli, K Macleod… - Nature …, 2008 - nature.com
… (d,e) Flow cytometry of the binding of phycoerythrin-conjugated mAb specific for α 4 (PE-α
4 ) or β 7 (PE-β 7 ; d) or of biotinylated AN1 gp120 (e) to 293T cells mock transfected or …
4 ) or β 7 (PE-β 7 ; d) or of biotinylated AN1 gp120 (e) to 293T cells mock transfected or …
Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with …
…, H Burris, I Judson, K Hazell, E Martinelli… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Everolimus is a selective mammalian target of rapamycin (mTOR) inhibitor with
promising anticancer activity. In order to identify a rationally based dose and schedule for …
promising anticancer activity. In order to identify a rationally based dose and schedule for …